|
Market Closed -
Euronext Paris
02:55:00 06/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 0.3260 EUR | +1.40% |
|
-2.54% | +9.40% |
| 16/09 | Nicox to present NCX 470 data at a conference |  |
| 11/09 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| Market Cap | 28.73M 32.24M 26.78M 24.38M 45.97M 3.11B 46.25M 324M 126M 1.58B 121M 118M 5.09B | P/E 2026 * |
-6.52x | P/E 2027 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 28.73M 32.24M 26.78M 24.38M 45.97M 3.11B 46.25M 324M 126M 1.58B 121M 118M 5.09B | EV / Sales 2026 * |
9.58x | EV / Sales 2027 * | 2.87x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALCOX | Real-time | |
CBOE
| COXp | Real-time | |
|
Deutsche Boerse AG
| NXOA | Delayed | |
|
CBOE
| 0RCQ | Real-time | |
|
Börse Stuttgart
| NXOA | Delayed | |
|
Boerse Muenchen
| NXOA | Real-time |
| 1 day | +1.40% | ||
| 1 week | -2.54% | ||
| Current month | -2.40% | ||
| 1 month | -14.44% | ||
| 3 months | -14.44% | ||
| 6 months | -20.10% | ||
| Current year | +9.40% |
| 1 week | 0.32 |  | 0.34 |
| 1 month | 0.32 | | 0.38 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.45 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Emmet Purtill
PRN | Corporate Officer/Principal | - | 01/01/2006 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/1/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/2/21 | Exercice | Chief Executive Officer | 10,000 | 0.0270% | ||
| 1/2/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.40% | -2.54% | -11.89% | -18.80% | 31.89M | |
| +0.02% | -3.41% | +36.11% | +115.09% | 1,019B | |
| -1.21% | -6.74% | +34.08% | +62.64% | 617B | |
| +1.12% | +0.54% | +13.62% | +79.94% | 464B | |
| -3.30% | -6.21% | +56.45% | +36.58% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | -0.04% | -3.58% | +21.73% | +50.48% | 369.72B | |
| Weighted average by Cap. | -0.05% | -3.54% | +28.50% | +70.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.37M 2.8M 2.55M 4.8M 324M 4.83M 33.78M 13.14M 165M 12.64M 12.36M 531M | 10M 11.22M 9.32M 8.49M 16M 1.08B 16.1M 113M 43.81M 552M 42.12M 41.2M 1.77B |
| Net income | -5M -5.61M -4.66M -4.24M -8M -540M -8.05M -56.31M -21.9M -276M -21.06M -20.6M -886M | 2M 2.24M 1.86M 1.7M 3.2M 216M 3.22M 22.52M 8.76M 110M 8.42M 8.24M 354M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | EUR 0.3260 | +1.40% | 69,781 |
| 02/10/26 | EUR 0.3215 | -1.08% | 280,187 |
| 01/10/26 | EUR 0.3250 | -2.69% | 114,849 |
| 30/09/26 | EUR 0.3340 | -1.76% | 210,549 |
| 29/09/26 | EUR 0.3400 | +1.64% | 141,180 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3260EUR
Average target price
1.000EUR
Spread / Average Target
+206.75%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
